The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1263-1265

  Luukkonen, Panu K ^a,e   Zhou, You ^a,d,e   Hyötyläinen, Tuulia ^c   Leivonen, Marja ^a   Arola, Johanna ^a   Orho Melander, Marju ^b   Orešič, Matej ^c   Yki Järvinen, Hannele ^a,e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c STENO DIABETES CENTER   (Denmark)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPIDOME; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; SPHINGOMYELIN; TRIACYLGLYCEROL; ACYLTRANSFERASE; MBOAT7 PROTEIN, HUMAN; MEMBRANE PROTEIN;

DISEASE SEVERITY; GENE; GENETIC VARIATION; GENOTYPE; HUMAN; LETTER; LIVER; LIVER FIBROSIS; LIVER INJURY; MBOAT7 GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; STEATOSIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY;

ACYLTRANSFERASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHATIDYLINOSITOLS;

EID: 85004009110     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.045     Document Type: Letter

References (10)

1. [1] Luukkonen, P.K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1167–1175.
2. [2] Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H.D., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47 (2015), 1443–1448.
3. [3] Mancina, R.M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology 150 (2016), 1219–1230, e6.
4. [4] D'Souza, K., Epand, R.M., Enrichment of phosphatidylinositols with specific acyl chains. Biochim Biophys Acta 1838 (2014), 1501–1508.
5. [5] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397, e10.
6. [6] Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
7. [7] Anderson, K.E., Kielkowska, A., Durrant, T.N., Juvin, V., Clark, J., Stephens, L.R., et al. Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP(2) in the mouse. PLoS One, 8, 2013, e58425.
8. [8] Rong, X., Wang, B., Dunham, M.M., Hedde, P.N., Wong, J.S., Gratton, E., et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife, 4, 2015.
9. [9] Pérez-Chacón, G., Astudillo, A.M., Balgoma, D., Balboa, M.A., Balsinde, J., Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim Biophys Acta 1791 (2009), 1103–1113.
10. [10] Loomba, R., Quehenberger, O., Armando, A., Dennis, E.A., Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 56 (2015), 185–192.